
Conference Coverage
about 1 month ago
Considering Alternatives to Vancomycin for MRSAabout 1 month ago
In a Matter of Months, MMR Vaccine Confidence Drops Significantlyabout 1 month ago
Clinical Takeaways From ViiV’s PASO DOBLE and CLARITY StudiesLatest Content

FDA Approves GSK’s Gepotidacin for Gonorrhea

Working With Young Clinicians to Identify, Treat Vector-Borne Diseases

FDA Plans to Review Already Approved RSV Immunizations

NYU’s Vaccine Center: A Short History With Significant Contributions

‘Complicating the Decision-Making’ for the Universal Birth Dose of the Hepatitis B Vaccine

Shorts










Podcasts
Videos
Contagion Digital Edition







Continuing Medical Education
All News

The federal agency approved Augmentin XR in just 2 months through the new CNPV pilot program, marking a potential step toward rebuilding domestic antibiotic manufacturing and addressing drug shortages.

House Lawmakers Probe FDA Over COVID-19 Vaccine Death Claims and Proposed Vaccine Regulation Changes
Questions raised about unverified FDA claims linking COVID-19 vaccines to pediatric deaths, and concerns that proposed vaccine testing requirements could delay access to key immunizations.

A large meta-analysis indicates opioid exposure may disrupt immunity and gut microbiota, increasing CDI vulnerability and potentially worsening clinical outcomes.

Angelica Cifuentes Kottkamp, MD, discusses how its location, breadth of experience, and opportunities afford clinicians the ability to see and treat a wide berth of diseases and infections.

Most clinical isolates identified as triazole-resistant Aspergillus niger by traditional clinical laboratory methods were revealed by DNA sequencing to be A tubingensis.

Population study corroborates 2019 FDA alert based on case reports of acute respiratory failure with TMP-SMX in healthy adolescents and young adults.

This week, read our coverage on the CDC ACIP meetings on the hepatitis B virus (HBV) vaccine, modeling data on the potential consequences of HBV infections, liver cancer, and mortality when delaying the birth dose to 2 months, our latest podcast, and more.

Lacking any safety data showing potential serious adverse effects, the committee decided to move forward with the recommendation “that the initial dose administered no earlier than 2 months of age.”

Due to repetitive and confusing language, the committee decided to amend the votes for clarity and will vote on 3 new recommendations on Friday.

Anticipating possible constraints on the approval of COVID-19 vaccines and their removal from the CDC pediatric vaccine schedule, a medical ethicist and legal scholar consider off-label vaccination.

A public health and farmworker coalition says agricultural spraying of medically important antibiotics and antifungals contributes to environmental resistance and warrants EPA cancellation.

New Centers for Disease Control and Prevention (CDC) data show rising early-season influenza activity, moderate 2024–2025 vaccine effectiveness, and updated 2025–2026 recommendations that include trivalent, thimerosal-free single-dose formulations and expanded access to FluMist.

A new analysis shows thousands of children could contract hepatitis B, leading to further complications and deaths, if the vaccine schedule recommendations are changed to later in a child's life.

Improving public awareness of appropriate antibiotic use could complement antibiotic stewardship programs worldwide.

WHO and UNAIDS warn of service disruptions, widening inequities, and mounting drug-resistance threats, while highlighting innovations and commitments needed to end AIDS as a public health threat.












































































































































































































































































































